PHGE: 分析师目标 $165 — AI 分析 (4月 2026)

BiomX Inc. is a clinical-stage microbiome company pioneering phage therapy to target and eliminate harmful bacteria associated with chronic diseases. Their innovative approach offers potential solutions for conditions like cystic fibrosis, IBD, and colorectal cancer.

Key Facts: Price: $2.52 Analyst Target: $165.00 AI Score: 39/100 Sector: Healthcare

公司概况

概要：

BiomX Inc. is revolutionizing microbiome therapeutics with its phage technology, precisely targeting and eliminating disease-causing bacteria. With a diverse pipeline addressing conditions like cystic fibrosis and IBD, BiomX offers a novel approach to combatting chronic diseases, positioning itself as a leader in the evolving field of phage-based therapies.

PHGE是做什么的？

Founded in 2015 and headquartered in Ness Ziona, Israel, BiomX Inc. is a clinical-stage biotechnology company focused on developing innovative products based on its proprietary phage technology. The company engineers natural bacteriophages, or phages, to selectively target and kill specific harmful bacteria within the human microbiome. This targeted approach aims to address the root cause of various chronic diseases and improve patient outcomes. BiomX's technology has applications in a range of conditions, including inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). Their lead product candidate, BX004, is a phage therapy designed to treat CF patients with chronic Pseudomonas aeruginosa respiratory infections and is currently in Phase 1b/2a clinical trials. Other pipeline products include BX005, a topical phage cocktail in Phase 1/2 clinical study targeting Staphylococcus aureus (S. aureus) associated with atopic dermatitis, and BX003, an orally administered phage cocktail in Phase 1b/2a targeting a bacterial target present in the gut of IBD and PSC patients. Additionally, BiomX is developing a colorectal cancer program utilizing engineered phages to target Fusobacterium nucleatum bacteria within the tumor microenvironment. BiomX's innovative approach and diverse pipeline position it as a key player in the growing field of microbiome-based therapeutics.

PHGE的投资论点是什么？

BiomX presents a notable market position due to its innovative phage technology and diverse pipeline targeting significant unmet medical needs. The company's lead candidate, BX004, has the potential to transform the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. Positive results from ongoing Phase 1b/2a clinical trials could serve as a major catalyst for the stock. Furthermore, BiomX's programs in IBD, atopic dermatitis, and colorectal cancer offer substantial long-term growth potential. With a market capitalization of $0.01 billion and a beta of 1.66, BiomX offers a high-risk, high-reward investment profile. Successful clinical trial outcomes and strategic partnerships could drive significant value creation for shareholders. The company's P/E ratio is -8.23, reflecting its current stage of development and focus on research and development.

PHGE在哪个行业运营？

BiomX operates within the rapidly evolving biotechnology industry, specifically focusing on microbiome-based therapeutics. The microbiome market is experiencing significant growth, driven by increasing awareness of the role of the microbiome in human health and disease. Competitors include companies like ADAP, BRTX, DWTX, EDSA, and ERNA, which are also developing novel therapies for various diseases. BiomX differentiates itself through its proprietary phage technology, which offers a highly targeted approach to eliminating harmful bacteria while preserving beneficial microbes. The company's focus on precision medicine positions it well to capitalize on the growing demand for personalized therapies.

Biotechnology

Healthcare

PHGE有哪些增长机遇？

Expansion of BX004 into additional indications: Beyond cystic fibrosis, BX004's phage therapy could be expanded to treat Pseudomonas aeruginosa infections in other patient populations, such as those with bronchiectasis or ventilator-associated pneumonia. The market for these indications is substantial, offering significant growth potential for BiomX. Timeline: 2-3 years.
Advancement of BX005 for atopic dermatitis: Positive results from the Phase 1/2 clinical study of BX005 could pave the way for further development and commercialization of this topical phage cocktail. The atopic dermatitis market is large and growing, driven by the increasing prevalence of the condition. Timeline: 3-4 years.
Development of BX003 for IBD and PSC: The Phase 1b/2a clinical trial of BX003 will provide valuable data on its safety and efficacy in treating IBD and PSC. Successful development of BX003 could address a significant unmet need in these patient populations. Timeline: 4-5 years.
Strategic partnerships and collaborations: BiomX could pursue strategic partnerships with pharmaceutical companies to accelerate the development and commercialization of its pipeline products. These partnerships could provide access to additional funding, expertise, and resources. Timeline: Ongoing.
Expansion of the colorectal cancer program: BiomX's colorectal cancer program offers significant long-term growth potential. The company could explore additional targets and payloads to enhance the efficacy of its engineered phages. The market for colorectal cancer therapies is substantial and growing. Timeline: 5+ years.

Developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections, currently in Phase 1b/2a clinical trials.
BX005, a topical phage cocktail, is in Phase 1/2 clinical study targeting Staphylococcus aureus (S. aureus), a bacteria associated with atopic dermatitis.
BX003, an orally administered phage cocktail, is in Phase 1b/2a targeting a bacterial target present in the gut of IBD and PSC patients.
Engaging in a colorectal cancer program utilizing engineered phage to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment.
Founded in 2015, BiomX has established itself as a pioneer in the field of phage-based therapeutics, with a focus on precision targeting of harmful bacteria.

PHGE提供哪些产品和服务？

Develops phage-based therapies to target and kill specific harmful bacteria.
Focuses on treating chronic diseases such as cystic fibrosis, IBD, and colorectal cancer.
Utilizes natural and engineered phage technologies for precision targeting.
Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
Develops topical and orally administered phage cocktails.
Targets bacteria that affect the appearance of skin, such as Staphylococcus aureus.
Creates engineered phage with various payloads to target bacteria within the tumor microenvironment.

PHGE如何赚钱？

Develops and patents phage-based therapeutic products.
Conducts clinical trials to demonstrate safety and efficacy.
Seeks regulatory approval from agencies like the FDA.
Potentially partners with pharmaceutical companies for commercialization.
Generates revenue through product sales and licensing agreements.

Patients suffering from chronic diseases such as cystic fibrosis, IBD, and colorectal cancer.
Healthcare providers who prescribe and administer BiomX's therapies.
Pharmaceutical companies that may partner with BiomX for commercialization.
Research institutions interested in phage technology and microbiome research.

Proprietary phage technology platform for precision targeting of bacteria.
Strong intellectual property portfolio protecting its phage-based therapies.
Clinical trial data demonstrating the safety and efficacy of its product candidates.
Expertise in microbiome research and phage engineering.
First-mover advantage in the development of phage-based therapeutics for certain indications.

什么因素可能推动PHGE股价上涨？

Upcoming: Data readout from Phase 1b/2a clinical trial of BX004 in cystic fibrosis patients.
Upcoming: Initiation of Phase 2 clinical trial of BX005 in atopic dermatitis patients.
Ongoing: Advancement of BX003 into later-stage clinical development for IBD and PSC.
Ongoing: Progress in the colorectal cancer program with engineered phages.
Ongoing: Potential for strategic partnerships and collaborations to accelerate development.

PHGE的主要风险是什么？

Potential: Failure to achieve positive results in clinical trials.
Potential: Regulatory delays or rejection of product candidates.
Ongoing: Competition from other biotechnology companies.
Ongoing: Dilution risk due to the need for additional financing.
Potential: Dependence on key personnel and scientific advisors.

PHGE的核心优势是什么？

Proprietary phage technology platform.
Diverse pipeline of product candidates targeting multiple indications.
Experienced management team with expertise in phage biology and drug development.
Strong intellectual property protection.

PHGE的劣势是什么？

Clinical-stage company with no currently approved products.
Reliance on successful clinical trial outcomes.
Limited financial resources.
High cash burn rate.

PHGE有哪些机遇？

Growing market for microbiome-based therapeutics.
Potential for strategic partnerships and collaborations.
Expansion into new indications and therapeutic areas.
Advancements in phage engineering and delivery technologies.

PHGE面临哪些威胁？

Regulatory hurdles and approval delays.
Competition from other biotechnology companies.
Potential for adverse events in clinical trials.
Uncertainty regarding reimbursement and market access.

PHGE的竞争对手是谁？

Adaptimmune Therapeutics plc — Focuses on T-cell therapies for cancer. — (ADAP)
BioRestorative Therapies, Inc. — Develops cell therapies for metabolic and disc/spine disorders. — (BRTX)
Dwelt Inc. — Focuses on cellular therapeutics for age-related diseases. — (DWTX)
Edessa Biotech, Inc. — Develops immunotherapy treatments for respiratory viruses. — (EDSA)
Eterna Therapeutics Inc. — Develops mRNA-based therapies. — (ERNA)

Key Metrics

Price: $2.52 (-4.67%)
Market Cap: $4.0M
MoonshotScore: 39/100

Analyst Price Target

Analyst Consensus Target: $165.00
Current Price: $2.52
Implied Upside: +6456.2%

常见问题

What does BiomX Inc. (PHGE) do?

BiomX Inc. (PHGE) is a clinical-stage biotechnology company that develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. Their innovative approach focuses on addressing the root cause of various chronic diseases, including inflammatory bowel diseases (IBD), cystic fibrosis (CF), and colorectal cancer (CRC). By selectively eliminating harmful bacteria while preserving beneficial microbes, BiomX aims to improve patient outcomes and revolutionize the treatment of microbiome-related conditions.

Is PHGE stock a good buy?

Evaluating whether PHGE stock is a good buy requires careful consideration of its potential and risks. BiomX's innovative phage technology and diverse pipeline offer significant growth opportunities, particularly with its lead candidate BX004 in Phase 1b/2a trials for cystic fibrosis. However, as a clinical-stage company with a market cap of $0.01 billion and a negative P/E ratio, PHGE carries substantial risk. Investors should weigh the potential for clinical trial success and strategic partnerships against the risks of regulatory hurdles, competition, and dilution before making an investment decision.

What are the risks of investing in PHGE?

Investing in PHGE carries several risks inherent to clinical-stage biotechnology companies. One significant risk is potential dilution, as the company may need to issue additional shares to fund its ongoing research and development activities. Another risk is the high cash burn rate associated with clinical trials and drug development. Regulatory risks also exist, as the company's product candidates must undergo rigorous review and approval processes before they can be commercialized. Failure to achieve positive clinical trial results or secure regulatory approval could significantly impact the company's value.

What catalysts could move PHGE stock?

Several catalysts could potentially move PHGE stock in the near future. Positive data readouts from the Phase 1b/2a clinical trial of BX004 in cystic fibrosis patients would likely be a significant catalyst, demonstrating the efficacy of BiomX's phage therapy. The initiation of a Phase 2 clinical trial for BX005 in atopic dermatitis could also generate positive momentum. Furthermore, any strategic partnerships or collaborations with pharmaceutical companies could provide a boost to the stock price. These upcoming events have the potential to drive investor interest and increase the stock's value.

What is PHGE stock price target?

As of March 3, 2026, there is no readily available analyst consensus price target for PHGE stock, likely due to its micro-cap status and the inherent uncertainty associated with clinical-stage biotechnology companies. A fair value estimate would require a detailed analysis of BiomX's pipeline, clinical trial data, and potential market opportunities. Investors should conduct their own due diligence and consider various factors, including the company's cash position, burn rate, and the likelihood of clinical trial success, to determine a reasonable valuation for PHGE stock.